Elizabeth A. Crago

Elizabeth A. Crago

Auto-generated profile, based on publicly available information

Elizabeth A. Crago

University of Pittsburgh School of Nursing Pittsburgh Pennsylvania USA

Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 January 2009 in Neurocritical Care
Verified
Journal Article
Closed access
PDF file
JFJ. Michael Frangiskakis
J. Michael Frangiskakis
MHMarilyn Hravnak
Marilyn Hravnak
ECElizabeth A. Crago
Elizabeth A. Crago
MTMasaki Tanabe
Masaki Tanabe
KKKevin Kip
Kevin Kip
BLBarry London
Barry London

17 August 2004 in Acta Neurologica Scandinavica
Verified
Journal Article
Closed access
PDF file
ECE. A. Crago
E. A. Crago
MKM. E. Kerr
M. E. Kerr
YKY. Kong
Y. Kong
MBM. Baldisseri
M. Baldisseri
MHM. Horowitz
M. Horowitz
AKA. Kassam
A. Kassam
Objectives – To determine the impact of cardiac complications (CdCs) on outcomes in patients with acute subarachnoid hemorrhage (SAH). Patients and methods – Eighty‐one adult aneurysmal SAH patients with a fisher grade >1 and/or a Hunt and Hess grade >2 were recruited for this study. CdCs were defined as electrocardiogram (ECG) changes, myocardial necrosis, arrythmias, or pulmonary edema. Outcomes were assessed at 3, 6 and 12 months by telephone interview using the Modified Rankin Scale (MRS), Glasgow Outcome Scale (GOS), Barthel Index and Medical Outcome study Short Form‐36 (SF‐36). Results – The CdCs occurred in 33% of patients. The most common CdCs were arrythmias and pulmonary edema (30%). There was no significant difference in mortality between the two groups. At 3 months there was a significant difference in the Barthel (P = 0.007) and the SF‐36 (P = 0.014) with trends in the GOS (P = 0.049) and the MRS (P = 0.063). At 6 months a significant difference remained in the SF‐36 (P = 0.028) and a trend in the Barthel (P = 0.069). Conclusion – Results show that CdCs may negatively impact outcomes in SAH patients up to 6 months following hemorrhage.


20 December 2021 in Epigenetics Communications
Verified
Journal Article
Open access
PDF file
Lacey HeinsbergLacey Heinsberg
Lacey Heinsberg
DWDaniel Weeks
Daniel Weeks
SASheila A. Alexander
Sheila A. Alexander
RMRyan Minster
Ryan Minster
PSPaula R. Sherwood
Paula R. Sherwood
YCYvette P. Conley
Yvette P. Conley
Background: Following aneurysmal subarachnoid hemorrhage (aSAH), the brain is susceptible to ferroptosis, a type of iron-dependent cell death. Therapeutic intervention targeting the iron homeostasis pathway shows promise for mitigating ferroptosis and improving recovery in animal models, but little work has been conducted in humans. DNA methylation (DNAm) plays a key role in gene expression and brain function, plasticity, and injury recovery, making it a potentially useful biomarker of outcomes or therapeutic target for intervention. Therefore, in this longitudinal, observational study, we examined the relationships between trajectories of DNAm in candidate genes related to iron homeostasis and acute (cerebral vasospasm and delayed cerebral ischemia) and long-term (Glasgow Outcome Scale [GOS, unfavorable = 1–3] and death) patient outcomes after aSAH.Results: Longitudinal, genome-wide DNAm data were generated from DNA extracted from post-aSAH cerebrospinal fluid (n= 260 participants). DNAm trajectories of 637 CpG sites in 36 candidate genes related to iron homeostasis were characterized over 13 days post-aSAH using group-based trajectory analysis, an unsupervised clustering method. Significant associations were identified between inferred DNAm trajectory groups at several CpG sites and acute and long-term outcomes. Among our results, cg25713625 in the STEAP3 metalloreductase gene (STEAP3) stood out. Specifically, in comparing the highest cg25713625 DNAm trajectory group with the lowest, we observed significant associations (i.e., based onp-values less than an empirical significance threshold) with unfavorable GOS at 3 and 12 months (OR= 11.7,p= 0.0006 andOR= 15.6,p= 0.0018, respectively) and death at 3 and 12 months (OR= 19.1,p= 0.0093 andOR= 12.8,p= 0.0041, respectively). These results were replicated in an independent sample (n= 100 participants) observing significant associations with GOS at 3 and 12 months (OR= 8.2,p= 0.001 andOR= 6.3,p= 0.0.0047, respectively) and death at 3 months (OR= 2.3,p= 0.008) and a suggestive association (i.e.,p-value < 0.05 not meeting an empirical significance threshold) with death at 12 months (OR= 2.0,p= 0.0272). In both samples, an additive effect of the DNAm trajectory group was observed as the percentage of participants with unfavorable long-term outcomes increased substantially with higher DNAm trajectory groups.Conclusion: Our results support a role for DNAm of cg25713625/STEAP3in recovery following aSAH. Additional research is needed to further explore the role of DNAm of cg25713625/STEAP3as a biomarker of unfavorable outcomes, or therapeutic target to improve outcomes, to translate these findings clinically.

29 December 2014 in Biological Research For Nursing
Verified
Journal Article
Open access
PDF file
ECElizabeth A. Crago
Elizabeth A. Crago
PSPaula R. Sherwood
Paula R. Sherwood
CBCatherine Bender
Catherine Bender
JBJeffrey Balzer
Jeffrey Balzer
DRDianxu Ren
Dianxu Ren
SPSamuel M. Poloyac
Samuel M. Poloyac
Biochemical mediators alter cerebral perfusion and have been implicated in delayed cerebral ischemia (DCI) and poor outcomes after aneurysmal subarachnoid hemorrhage (aSAH). Estrogens (estrone [E1] and estradiol [E2]) are mediators with neuroprotective properties that could play a role in DCI. This study explored associations between plasma estrogen levels and outcomes following aSAH. Plasma samples from 1–4, 4–6, and 7–10 days after hemorrhage from 99 adult aSAH patients were analyzed for estrogen levels using liquid chromatography tandem mass spectrometry. DCI was operationalized as radiographic/ultrasonic evidence of impaired cerebral blood flow accompanied by neurological deterioration. Outcomes were assessed using the Modified Rankin Scale at 3 and 12 months after hemorrhage. Statistical analysis included correlation, regression, and group-based trajectory. Higher E1 and E2 levels were associated with higher Hunt and Hess grade (E1, p = .01; E2, p = .03), the presence of DCI (E1, p = .02; E2, p = .02), and poor 3-month outcomes (E1, p = .002; E2, p = .002). Trajectory analysis identified distinct populations over time for E1 (61% E1 high) and E2 (68% E2 high). Patients in higher trajectory groups had higher Fisher grades (E1, p = .008; E2, p = .01), more frequent DCI (E1, p = .04; E2, p = .08), and worse 3-month outcomes (E1, p = .01; E2, p = .004) than low groups. These results provide the first clinical evidence that plasma E1 and E2 concentrations are associated with severity of injury and outcomes after aSAH.

7 January 2023 in World Neurosurgery
Verified
Journal Article
Closed access
AMAditya M. Mittal
Aditya M. Mittal
MPMatthew Pease
Matthew Pease
DMDavid McCarthy
David McCarthy
ALAndrew Legarreta
Andrew Legarreta
RBRaouf Belkhir
Raouf Belkhir
BGBradley A. Gross
Bradley A. Gross